Non-cross-reactive anti IgG antibodies

Patent metadata

Field	Value
Publication number	US-9957331-B2
Application number	US-201013502687-A
Country	US
Kind code	B2
Filing date	Oct 18, 2010
Priority date	Oct 19, 2009
Publication date	May 1, 2018
Grant date	May 1, 2018

Abstract

Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG 1 that comprises a kappa light chain constant domain.

First claim

The invention claimed is:

1. A hybridoma cell line selected from the group consisting of DSM ACC3006, DSM ACC3007 and DSM ACC3008.

2. An antibody produced by one of the hybridoma cell lines of claim 1 .

3. The antibody of claim 2 , wherein the hybridoma cell line is DSM ACC3006.

4. The antibody of claim 2 , wherein the hybridoma cell line is DSM ACC3007.

5. The antibody of claim 2 , wherein the hybridoma cell line is DSM ACC3008.

6. A method for detecting a human or humanized therapeutic antibody comprising a human kappa light chain, or a Fab fragment thereof, in a sample obtained from an experimental animal comprising the steps of
a) providing a sample to be analyzed, the sample obtained from an experimental animal selected from the group consisting of a canine, a rhesus-monkey, a marmoset, a baboon, and a cynomolgus monkey,
b) incubating said sample with a capture antibody that is bound to a solid phase, wherein said capture antibody is the antibody of any one of claims 3 to 5 ,
c) incubating said sample with a detection antibody that is conjugated to a detectable label so as to form a complex, wherein said detection antibody is the antibody of any one of claims 3 to 5 , and
d) detecting the detectable label on the detection antibody, thereby detecting the therapeutic antibody or Fab fragment thereof.

7. The method of claim 6 , wherein the capture antibody is conjugated to biotin and immobilized to the solid phase via avidin or streptavidin.

8. The method of claim 6 , wherein the detectable label is digoxigenin and the step of detecting the detectable label is performed via an antibody against digoxigenin.

9. The method of claim 6 , further comprising correlating the detectable label that is conjugated to the detection antibody to a concentration of the therapeutic antibody, or Fab fragment thereof, in the sample.

10. The method of claim 6 , further comprising washing the sample after incubating the sample with the capture antibody bound to the solid phase.

11. The method of claim 7 , wherein the detectable label is digoxigenin and the step of detecting the detectable label is performed via an antibody against digoxigenin.

12. An antibody composition, comprising a mixture of antibodies produced by hybridoma cell line DSM ACC3006, hybridoma cell line DSM ACC3007, and/or hybridoma cell line DSM ACC3008.

Assignees

• Essig Ulrich
• Klostermann Stefan
• Kowalewsky Frank
• Stubenrauch Kay Gunnar
• Vogel Rudolf
• Wessels Uwe
• Hoffmann La Roche

Inventors

• Essig Ulrich
• Klostermann Stefan
• Kowalewsky Frank
• Stubenrauch Kay-Gunnar
• Vogel Rudolf
• Wessels Uwe

Classifications

• G01N33/6854

  Immunoglobulins · CPC title

• C07K16/4283 Primary

  against an allotypic or isotypic determinant on Ig · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C12N5/06

  Animal cells or tissues; Human cells or tissues (preservation of excised living parts A01N1/10) · CPC title

• G01N33/53

  Immunoassay; Biospecific binding assay; Materials therefor · CPC title